RPCEC00000445
Not Yet Recruiting
N/A
Evaluation of biomarkers associated with the clinical effect of the CIMAvax-EGF® vaccine in patients with advanced stages of non-small cell lung cancer (NSCLC). Exploratory Study of Biomarkers - EMA-Lung
Center of Molecular Immunology (CIM)0 sites20 target enrollmentJune 20, 2024
Conditionson-Small Cell Lung Cancer (NSCLC)
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- on-Small Cell Lung Cancer (NSCLC)
- Sponsor
- Center of Molecular Immunology (CIM)
- Enrollment
- 20
- Status
- Not Yet Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Patients who have signed the informed consent for the research .
- •2\. Patients of any sex and older than 19 years.
- •3\. Patients who meet the diagnostic criteria.
- •4\. Patients with clinical status criteria (ECOG) of 0 a2\.
- •5\. Patients who have achieved partial response or stable disease after the first line of onco\-specific treatment.
- •6\. Patients with a life expectancy of 6 months or more.
Exclusion Criteria
- •1\. Patients of childbearing potential who are not using an adequate method of contraception (intrauterine devices, hormonal contraceptives, barrier methods or tubal ligation). In the case of the male sex (vasectomy, use of condoms) while the treatment lasts
- •2\. Pregnant, breastfeeding or postpartum patients.
- •3\. Patients who are participating in another clinical trial or who have been treated with specific immunotherapy with CIMAvax\-EGF® in the previous 6 months.
- •4\. Patients with uncontrolled intercurrent diseases that include, but are not limited to: active infections, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, diabetes mellitus, arterial hypertension and psychiatric diseases that imply the incompetence of the subject.
- •5\. Patients with acute allergic states or history of severe allergic reactions.
- •6\. Patients with brain metastasis.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not Yet Recruiting
N/A
CIMAvax-EGF/Lung cancer/Biomarkers/Prospective CTAdvanced non small cell lung cancerCarcinoma, Non-Small-Cell LungCarcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsLung DiseasesRespiratory Tract DiseasesRPCEC00000392Center of Molecular Immunology130
Not Yet Recruiting
N/A
Phyisician Led CIMAvax-EGF lung biomarkersAdvanced non small cell lung cancerCarcinoma, Non-Small-Cell LungCarcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsLung DiseasesRespiratory Tract DiseasesRPCEC00000355Center of Molecular Immunology (CIM)140
Not Yet Recruiting
N/A
Evaluation study of biological markers involved in cardiovascular diseases in childhoodcardiovascular diseasesJPRN-UMIN000002281Kyoto university100
Not Yet Recruiting
Phase 4
Evaluation of Biomarkers for the Assessment of Disease Activity of Eosinophilic Esophagitis (EoE) in ChildreK20K21T78.1OesophagitisGastro-oesophageal reflux diseaseOther adverse food reactions, not elsewhere classifiedDRKS00014688Abteilung für Gastroenterologie und HepatologieKinderklinik Erlangen100
Completed
N/A
An exploratory study to evaluate biomarkers of prospective multicenter observational study of atezolizumab in patients with locally advanced or metastatic non-small cell lung cancer :J-TAIon-small cell lung cancerJPRN-UMIN000035567Medical Affairs, CHUGAI PHARMACEUTICAL CO., LTD.250